Do analysts prefer SNYR or PHXM?

Synergy CHC currently has a consensus price target of $6.25, suggesting a potential upside of 3,565.69%. Given Synergy CHC's stronger consensus rating and higher possible upside, equities analysts plainly believe Synergy CHC is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, SNYR or PHXM?

PHAXIAM Therapeutics has lower revenue, but higher earnings than Synergy CHC. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synergy CHC $30.38M 0.08 -$12.34M -$1.40 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is SNYR or PHXM more profitable?

PHAXIAM Therapeutics has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Company Net Margins Return on Equity Return on Assets Synergy CHC -60.02% N/A -30.30% PHAXIAM Therapeutics N/A N/A N/A

Do analysts recommend MYNZ or SNYR?

Synergy CHC has a consensus target price of $6.25, indicating a potential upside of 3,565.69%. Given Synergy CHC's stronger consensus rating and higher possible upside, analysts clearly believe Synergy CHC is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Synergy CHC 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, MYNZ or SNYR?

Synergy CHC has higher revenue and earnings than Mainz Biomed. Synergy CHC is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mainz Biomed $659.94K 14.83 -$21.65M -$65.60 N/A Synergy CHC $30.38M 0.08 -$12.34M -$1.40 N/A

Is MYNZ or SNYR more profitable?

Mainz Biomed has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A Synergy CHC -60.02% N/A -30.30%

Does the media refer more to MYNZ or SNYR?

In the previous week, Synergy CHC had 2 more articles in the media than Mainz Biomed. MarketBeat recorded 3 mentions for Synergy CHC and 1 mentions for Mainz Biomed. Synergy CHC's average media sentiment score of 0.96 beat Mainz Biomed's score of 0.75 indicating that Synergy CHC is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mainz Biomed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Synergy CHC 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SNYR or ASBP?

Synergy CHC presently has a consensus target price of $6.25, indicating a potential upside of 3,565.69%. Given Synergy CHC's stronger consensus rating and higher possible upside, research analysts clearly believe Synergy CHC is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, SNYR or ASBP?

Synergy CHC has higher revenue and earnings than Aspire Biopharma. Synergy CHC is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synergy CHC $30.38M 0.08 -$12.34M -$1.40 N/A Aspire Biopharma $34.56K 272.08 -$24.48M -$116.67 N/A

Is SNYR or ASBP more profitable?

Aspire Biopharma has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Company Net Margins Return on Equity Return on Assets Synergy CHC -60.02% N/A -30.30% Aspire Biopharma N/A N/A -398.04%

Does the media refer more to SNYR or ASBP?

In the previous week, Synergy CHC and Synergy CHC both had 3 articles in the media. Synergy CHC's average media sentiment score of 0.96 beat Aspire Biopharma's score of 0.45 indicating that Synergy CHC is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synergy CHC 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aspire Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SNYR or BCDA more profitable?

BioCardia has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of 0.00% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets Synergy CHC -60.02% N/A -30.30% BioCardia N/A -5,456.14% -232.75%

Do analysts recommend SNYR or BCLI?

Synergy CHC presently has a consensus target price of $6.25, suggesting a potential upside of 3,565.69%. Given Synergy CHC's stronger consensus rating and higher possible upside, equities analysts clearly believe Synergy CHC is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is SNYR or BCLI more profitable?

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Company Net Margins Return on Equity Return on Assets Synergy CHC -60.02% N/A -30.30% Brainstorm Cell Therapeutics N/A N/A -519.50%

Does the media favor SNYR or BCLI?

In the previous week, Synergy CHC had 2 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 3 mentions for Synergy CHC and 1 mentions for Brainstorm Cell Therapeutics. Synergy CHC's average media sentiment score of 0.96 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Synergy CHC is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synergy CHC 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Brainstorm Cell Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Synergy CHC (SNYR) Competitors

$0.17 +0.00 (+1.97%)

As of 07/24/2026 03:59 PM Eastern

Compare

SNYR vs. PHXM, MYNZ, ASBP, BCDA, and BCLI

Should you buy Synergy CHC stock or one of its competitors? MarketBeat compares Synergy CHC with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Synergy CHC include PHAXIAM Therapeutics (PHXM), Mainz Biomed (MYNZ), Aspire Biopharma (ASBP), BioCardia (BCDA), and Brainstorm Cell Therapeutics (BCLI). These companies are all part of the "pharmaceutical products" industry.

How does Synergy CHC compare to PHAXIAM Therapeutics?

Synergy CHC (NASDAQ:SNYR) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

PHAXIAM Therapeutics has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%.

Company	Net Margins	Return on Equity	Return on Assets
Synergy CHC	-60.02%	N/A	-30.30%
PHAXIAM Therapeutics	N/A	N/A	N/A

Synergy CHC has a beta of -0.14, suggesting that its stock price is 114% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market.

PHAXIAM Therapeutics has lower revenue, but higher earnings than Synergy CHC.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synergy CHC	$30.38M	0.08	-$12.34M	-$1.40	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Synergy CHC currently has a consensus price target of $6.25, suggesting a potential upside of 3,565.69%. Given Synergy CHC's stronger consensus rating and higher possible upside, equities analysts plainly believe Synergy CHC is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synergy CHC	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 32.9% of Synergy CHC shares are held by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Synergy CHC had 3 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 3 mentions for Synergy CHC and 0 mentions for PHAXIAM Therapeutics. Synergy CHC's average media sentiment score of 0.96 beat PHAXIAM Therapeutics' score of 0.00 indicating that Synergy CHC is being referred to more favorably in the media.

Company	Overall Sentiment
Synergy CHC	Positive
PHAXIAM Therapeutics	Neutral

Summary

Synergy CHC beats PHAXIAM Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Synergy CHC compare to Mainz Biomed?

Mainz Biomed (NASDAQ:MYNZ) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Mainz Biomed has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Synergy CHC has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market.

Synergy CHC has a consensus target price of $6.25, indicating a potential upside of 3,565.69%. Given Synergy CHC's stronger consensus rating and higher possible upside, analysts clearly believe Synergy CHC is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Synergy CHC	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Synergy CHC had 2 more articles in the media than Mainz Biomed. MarketBeat recorded 3 mentions for Synergy CHC and 1 mentions for Mainz Biomed. Synergy CHC's average media sentiment score of 0.96 beat Mainz Biomed's score of 0.75 indicating that Synergy CHC is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mainz Biomed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Synergy CHC	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Synergy CHC has higher revenue and earnings than Mainz Biomed. Synergy CHC is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	14.83	-$21.65M	-$65.60	N/A
Synergy CHC	$30.38M	0.08	-$12.34M	-$1.40	N/A

Mainz Biomed has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Synergy CHC	-60.02%	N/A	-30.30%

Summary

Synergy CHC beats Mainz Biomed on 8 of the 13 factors compared between the two stocks.

How does Synergy CHC compare to Aspire Biopharma?

Synergy CHC (NASDAQ:SNYR) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

Synergy CHC has higher revenue and earnings than Aspire Biopharma. Synergy CHC is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synergy CHC	$30.38M	0.08	-$12.34M	-$1.40	N/A
Aspire Biopharma	$34.56K	272.08	-$24.48M	-$116.67	N/A

Aspire Biopharma has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%.

Company	Net Margins	Return on Equity	Return on Assets
Synergy CHC	-60.02%	N/A	-30.30%
Aspire Biopharma	N/A	N/A	-398.04%

19.2% of Aspire Biopharma shares are held by institutional investors. 32.9% of Synergy CHC shares are held by insiders. Comparatively, 5.8% of Aspire Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Synergy CHC presently has a consensus target price of $6.25, indicating a potential upside of 3,565.69%. Given Synergy CHC's stronger consensus rating and higher possible upside, research analysts clearly believe Synergy CHC is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synergy CHC	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Synergy CHC has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market.

In the previous week, Synergy CHC and Synergy CHC both had 3 articles in the media. Synergy CHC's average media sentiment score of 0.96 beat Aspire Biopharma's score of 0.45 indicating that Synergy CHC is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synergy CHC	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aspire Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Synergy CHC beats Aspire Biopharma on 9 of the 14 factors compared between the two stocks.

How does Synergy CHC compare to BioCardia?

Synergy CHC (NASDAQ:SNYR) and BioCardia (NASDAQ:BCDA) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

BioCardia has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Synergy CHC's return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synergy CHC	-60.02%	N/A	-30.30%
BioCardia	N/A	-5,456.14%	-232.75%

Synergy CHC has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market. Comparatively, BioCardia has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

BioCardia has lower revenue, but higher earnings than Synergy CHC. BioCardia is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synergy CHC	$30.38M	0.08	-$12.34M	-$1.40	N/A
BioCardia	N/A	N/A	-$8.23M	-$0.91	N/A

In the previous week, Synergy CHC had 1 more articles in the media than BioCardia. MarketBeat recorded 3 mentions for Synergy CHC and 2 mentions for BioCardia. Synergy CHC's average media sentiment score of 0.96 beat BioCardia's score of 0.50 indicating that Synergy CHC is being referred to more favorably in the media.

Company	Overall Sentiment
Synergy CHC	Positive
BioCardia	Positive

20.6% of BioCardia shares are held by institutional investors. 32.9% of Synergy CHC shares are held by company insiders. Comparatively, 17.4% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Synergy CHC currently has a consensus price target of $6.25, suggesting a potential upside of 3,565.69%. BioCardia has a consensus price target of $25.00, suggesting a potential upside of 2,840.83%. Given Synergy CHC's stronger consensus rating and higher probable upside, analysts clearly believe Synergy CHC is more favorable than BioCardia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synergy CHC	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioCardia	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Synergy CHC beats BioCardia on 10 of the 15 factors compared between the two stocks.

How does Synergy CHC compare to Brainstorm Cell Therapeutics?

Synergy CHC (NASDAQ:SNYR) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Synergy CHC presently has a consensus target price of $6.25, suggesting a potential upside of 3,565.69%. Given Synergy CHC's stronger consensus rating and higher possible upside, equities analysts clearly believe Synergy CHC is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synergy CHC	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Brainstorm Cell Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 32.9% of Synergy CHC shares are held by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%.

Company	Net Margins	Return on Equity	Return on Assets
Synergy CHC	-60.02%	N/A	-30.30%
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

Synergy CHC has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Synergy CHC. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synergy CHC	$30.38M	0.08	-$12.34M	-$1.40	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A

In the previous week, Synergy CHC had 2 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 3 mentions for Synergy CHC and 1 mentions for Brainstorm Cell Therapeutics. Synergy CHC's average media sentiment score of 0.96 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Synergy CHC is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synergy CHC	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Synergy CHC beats Brainstorm Cell Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Synergy CHC News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNYR vs. The Competition

Export

Metric	Synergy CHC	CONS PD Industry	Staples Sector	NASDAQ Exchange
Market Cap	$2.52M	$30.34B	$16.40B	$12.26B
Dividend Yield	N/A	3.29%	3.32%	9.79%
P/E Ratio	-0.12	73.99	26.01	23.64
Price / Sales	0.08	1.53	44.31	88.99
Price / Cash	N/A	31.86	16.45	59.64
Price / Book	-0.08	10.94	5.70	6.07
Net Income	-$12.34M	$1.33B	$659.99M	$331.99M
7 Day Performance	-8.48%	-6.09%	-1.65%	-0.63%
1 Month Performance	-16.01%	-1.69%	0.82%	-2.00%
1 Year Performance	-95.50%	-22.58%	-14.13%	13.62%

Synergy CHC Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNYR Synergy CHC	3.0883 of 5 stars	$0.17 +2.0%	$6.25 +3,565.7%	-95.7%	$2.52M	$30.38M	N/A	40	Short Interest Decrease
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
MYNZ Mainz Biomed	0.4499 of 5 stars	$1.16 flat	N/A	-44.2%	$10.51M	$659.94K	N/A	30
ASBP Aspire Biopharma	0.1847 of 5 stars	$7.95 +5.4%	N/A	-98.8%	$10.29M	$34.56K	N/A	N/A
BCDA BioCardia	3.2541 of 5 stars	$0.90 -2.5%	$25.00 +2,680.9%	-63.2%	$10.23M	N/A	N/A	40	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNYR) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synergy CHC (SNYR) Competitors

SNYR vs. PHXM, MYNZ, ASBP, BCDA, and BCLI

How does Synergy CHC compare to PHAXIAM Therapeutics?

Summary

How does Synergy CHC compare to Mainz Biomed?

Summary

How does Synergy CHC compare to Aspire Biopharma?

Summary

How does Synergy CHC compare to BioCardia?

Summary

How does Synergy CHC compare to Brainstorm Cell Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNYR vs. The Competition

Synergy CHC Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synergy CHC (SNYR) Competitors

SNYR vs. PHXM, MYNZ, ASBP, BCDA, and BCLI

How does Synergy CHC compare to PHAXIAM Therapeutics?

Is SNYR or PHXM more profitable?

Which has more volatility and risk, SNYR or PHXM?

Which has stronger valuation and earnings, SNYR or PHXM?

Do analysts prefer SNYR or PHXM?

Do insiders and institutionals believe in SNYR or PHXM?

Does the media refer more to SNYR or PHXM?

Summary

How does Synergy CHC compare to Mainz Biomed?

Which has more volatility & risk, MYNZ or SNYR?

Do analysts recommend MYNZ or SNYR?

Does the media refer more to MYNZ or SNYR?

Which has better earnings & valuation, MYNZ or SNYR?

Is MYNZ or SNYR more profitable?

Summary

How does Synergy CHC compare to Aspire Biopharma?

Which has stronger valuation & earnings, SNYR or ASBP?

Is SNYR or ASBP more profitable?

Do insiders and institutionals have more ownership in SNYR or ASBP?

Do analysts rate SNYR or ASBP?

Which has more volatility & risk, SNYR or ASBP?

Does the media refer more to SNYR or ASBP?

Summary

How does Synergy CHC compare to BioCardia?

Is SNYR or BCDA more profitable?

Which has more risk & volatility, SNYR or BCDA?

Which has preferable valuation and earnings, SNYR or BCDA?

Does the media favor SNYR or BCDA?

Do institutionals and insiders hold more shares of SNYR or BCDA?

Do analysts recommend SNYR or BCDA?

Summary

How does Synergy CHC compare to Brainstorm Cell Therapeutics?

Do analysts recommend SNYR or BCLI?

Do institutionals & insiders hold more shares of SNYR or BCLI?

Is SNYR or BCLI more profitable?

Which has more volatility & risk, SNYR or BCLI?

Which has stronger valuation & earnings, SNYR or BCLI?

Does the media favor SNYR or BCLI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNYR vs. The Competition

Synergy CHC Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools